We accelerate product development.
MED Institute is dedicated to bringing new medical products to market that are safe and effective for patients. From concept to commercialization, our team has the knowledge and experience to guide your product through the complex steps required for market approval.
We can help you find your regulatory path through the development process.
MORE ABOUT REGULATORY SERVICES
We have helped medical devices within 42 medical specialties reach markets around the world.
ABOUT MED INSTITUTE
We have over 250 accredited tests and are actively validating new methods.
MORE ABOUT TESTING SERVICES
We provide thoughtful guidance and quality clinical trial services to our clients, focusing on safety and effectiveness.
MORE ABOUT CLINICAL SERVICES
Highest Quality. Minimal Defects.
We are committed to consistently performing services with high quality and minimal defects. Audits by external parties and client feedback provide input to continuous improvement. For client surveys sent in the last two quarters, we received ratings of 4.80/5 points (4).
Contact Us
Our Services
Accelerate your product development.
Research Collaboration with the FDA
Since 2016, we have collaborated with the FDA on a research project to assess radiofrequency (RF) induced heating of passive metallic medical devices during magnetic resonance imaging (MRI). The information learned will provide engineers an understanding of thresholds for heating. It will also support the design of appropriate MRI safety testing strategies.
LEARN MORE
Latest News
The latest news and thought leadership from MED Institute.
-
CDRH Science Update: Research Programs Webpages in the Office of Science and Engineering Laboratories at CDRH
March 1, 2016The Office of Science and Engineering Laboratories (OSEL)/Center for Devices and Radiological Health (CDRH) is pleased to...
OUR COMMITTMENT
We are committed to consistently performing services with high quality, that deliver exceptional results, and add value to the client’s business.
For client surveys sent in the last two quarters, we received ratings of 4.80/5 points (4).
